BREAKING: NVDA loses $175 billion in 8 minutes

It's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, with annual revenue up nearly 100%. So why did the stock abruptly plunge following the earnings release – losing $175 billion in just 8 minutes?

DMAC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.20%

Insider Buying (Last 12 Months): $3,000,000.00

Insider Selling (Last 12 Months): $0.00

DiaMedica Therapeutics Insider Trading History Chart

DiaMedica Therapeutics Share Price & Price History

^$4.19

▲ +0.17 (4.23%)

As of 11/21/2024 01:00 AM ET

Days: 30 | 90 | 365

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

DiaMedica Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/28/2024	Koch Thomas Von	Major Shareholder	Buy	1,200,000	$2.50	$3,000,000.00	5,526,435
6/23/2023	David J Wambeke	Insider	Buy	38,364	$3.91	$150,003.24	507,114
6/23/2023	Dietrich John Pauls	CEO	Buy	12,787	$3.91	$49,997.17	68,591
6/23/2023	Koch Thomas Von	Major Shareholder	Buy	1,470,588	$3.40	$4,999,999.20	4,326,435
6/23/2023	Randall Michael Giuffre	Director	Buy	65,000	$3.91	$254,150.00	360,355
6/23/2023	Scott Kellen	CFO	Buy	10,000	$3.91	$39,100.00	32,290
4/10/2023	David J Wambeke	Insider	Buy	468,750	$1.60	$750,000.00	468,750
12/8/2022	Randall Michael Giuffre	Director	Buy	20,000	$1.40	$28,000.00	223,146
12/6/2022	Randall Michael Giuffre	Director	Buy	2,300	$1.35	$3,105.00	180,572
12/1/2022	Randall Michael Giuffre	Director	Buy	46,133	$1.20	$55,359.60	177,453
11/29/2022	Randall Michael Giuffre	Director	Buy	18,125	$1.19	$21,568.75	128,350
11/16/2022	Dietrich John Pauls	CEO	Buy	20,000	$1.21	$24,200.00	55,804
7/8/2022	Koch Thomas Von	Major Shareholder	Buy	207,974	$1.33	$276,605.42	2,855,827

$2 Trillion Disappears Because of Fed's Secretive New Move

From Stansberry Research | Ad

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Click here to see his new research now.

SEC Filings (Institutional Ownership Changes) for DiaMedica Therapeutics (NASDAQ:DMAC)

10.12% of DiaMedica Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

DiaMedica Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	306,958	$1.29M	0.0%	+29.6%	0.718%
11/15/2024	Point72 Asia Singapore Pte. Ltd.	9,498	$40K	0.0%	N/A	0.022%
10/18/2024	Blue Trust Inc.	44,247	$0.19M	0.0%	N/A	0.104%
8/16/2024	Magnolia Capital Advisors LLC	29,500	$87K	0.0%	N/A	0.069%
5/10/2024	Vanguard Group Inc.	1,013,522	$2.81M	0.0%	+26.3%	2.670%
2/15/2024	Paragon Associates & Paragon Associates II Joint Venture	500,000	$1.42M	3.3%	+6.4%	1.318%
2/7/2024	Avantax Advisory Services Inc.	12,500	$36K	0.0%	N/A	0.033%
11/15/2023	Stonebridge Capital Advisors LLC	20,000	$52K	0.0%	N/A	0.053%
11/13/2023	EAM Investors LLC	212,512	$0.55M	0.1%	-21.4%	0.560%
11/9/2023	Bleichroeder LP	222,317	$0.57M	0.1%	-24.4%	0.586%
11/1/2023	Jacob Asset Management of New York LLC	168,730	$0.44M	0.6%	-15.1%	0.445%
8/30/2023	Cooperman Leon G	875,993	$3.78M	0.2%	+0.9%	2.308%
8/10/2023	Jacob Asset Management of New York LLC	198,730	$0.86M	1.0%	-15.0%	0.738%
8/2/2023	Catalyst Financial Partners LLC	36,267	$0.16M	0.1%	+44.4%	0.135%
4/11/2023	Catalyst Financial Partners LLC	25,110	$38K	0.0%	+73.5%	0.095%
5/12/2022	Jacob Asset Management of New York LLC	265,000	$0.66M	0.4%	-3.6%	1.002%
2/15/2022	Stonepine Capital Management LLC	1,194,670	$4.46M	2.0%	+620.7%	4.519%
11/15/2021	Marshall Wace LLP	10,031	$40K	0.0%	-93.6%	0.053%
11/15/2021	Manatuck Hill Partners LLC	273,100	$1.10M	0.4%	-52.1%	1.454%
11/12/2021	Stonepine Capital Management LLC	165,775	$0.67M	0.3%	-60.5%	0.882%
11/12/2021	Jump Financial LLC	18,300	$73K	0.0%	N/A	0.097%
11/9/2021	BlackRock Inc.	55,970	$0.23M	0.0%	-8.6%	0.298%
8/25/2021	Marshall Wace LLP	155,662	$0.69M	0.0%	+104.9%	0.829%
8/16/2021	State Street Corp	30,217	$0.13M	0.0%	N/A	0.161%
8/16/2021	Corriente Advisors LLC	203,641	$0.91M	0.5%	-76.6%	1.084%
8/16/2021	Marshall Wace LLP	155,662	$0.69M	0.0%	+104.9%	0.829%
8/13/2021	Renaissance Technologies LLC	94,100	$0.42M	0.0%	-38.5%	0.501%
8/13/2021	Geode Capital Management LLC	133,569	$0.59M	0.0%	+4.0%	0.711%
8/13/2021	Vanguard Group Inc.	786,266	$3.50M	0.0%	-7.1%	4.185%
8/12/2021	Trexquant Investment LP	17,019	$76K	0.0%	N/A	0.091%
8/12/2021	Dimensional Fund Advisors LP	14,074	$63K	0.0%	N/A	0.075%
8/12/2021	JPMorgan Chase & Co.	8,299	$37K	0.0%	N/A	0.044%
8/12/2021	Bank of Montreal Can	142,846	$0.69M	0.0%	+36.7%	0.760%
5/21/2021	Citadel Advisors LLC	20,601	$0.19M	0.0%	N/A	0.110%
5/19/2021	Squarepoint Ops LLC	35,536	$0.33M	0.0%	N/A	0.189%
5/18/2021	Millennium Management LLC	70,281	$0.64M	0.0%	+72.0%	0.374%
5/18/2021	Point72 Asset Management L.P.	552,250	$5.05M	0.0%	-31.0%	2.940%
5/18/2021	Corriente Advisors LLC	870,228	$7.96M	2.9%	+7.8%	4.632%
5/18/2021	Citadel Advisors LLC	20,601	$0.19M	0.0%	N/A	0.110%
5/13/2021	Barclays PLC	3,412	$31K	0.0%	N/A	0.018%
5/13/2021	Renaissance Technologies LLC	153,100	$1.40M	0.0%	+35.0%	0.815%
5/13/2021	Bank of New York Mellon Corp	40,576	$0.37M	0.0%	-5.4%	0.216%
5/13/2021	Bank of Montreal Can	104,524	$0.98M	0.0%	+27.7%	0.556%
5/12/2021	Northern Trust Corp	85,026	$0.78M	0.0%	-29.7%	0.453%
5/12/2021	Geode Capital Management LLC	128,468	$1.18M	0.0%	+23.9%	0.684%
5/12/2021	Granite Point Capital Management L.P.	184,380	$1.69M	0.1%	-66.3%	0.981%
5/11/2021	EAM Investors LLC	108,232	$0.99M	0.1%	-1.6%	0.576%
5/7/2021	BlackRock Inc.	60,165	$0.55M	0.0%	+7.9%	0.320%
4/27/2021	Dorsey Wright & Associates	3,937	$36K	0.4%	N/A	0.021%
2/24/2021	Virtu Financial LLC	15,712	$0.16M	0.0%	N/A	0.084%
2/17/2021	Jane Street Group LLC	12,537	$0.13M	0.0%	N/A	0.067%
2/16/2021	ExodusPoint Capital Management LP	13,160	$0.13M	0.0%	N/A	0.070%
2/12/2021	Stonepine Capital Management LLC	950,000	$9.63M	7.4%	-17.1%	5.070%
2/11/2021	Northern Trust Corp	120,989	$1.23M	0.0%	+3.6%	0.646%
2/11/2021	Valeo Financial Advisors LLC	5,000	$51K	0.0%	N/A	0.027%
2/10/2021	Renaissance Technologies LLC	113,400	$1.15M	0.0%	+18.1%	0.605%
2/9/2021	Bank of New York Mellon Corp	42,905	$0.44M	0.0%	+218.5%	0.229%
2/6/2021	Granite Point Capital Management L.P.	546,855	$5.55M	0.3%	-15.5%	2.918%
2/5/2021	BlackRock Inc.	55,781	$0.57M	0.0%	+27.4%	0.298%
11/17/2020	Nantahala Capital Management LLC	756,193	$3.21M	0.1%	+0.8%	4.035%
11/16/2020	Point72 Asset Management L.P.	800,000	$3.39M	0.0%	N/A	4.269%
11/16/2020	Worth Venture Partners LLC	42,887	$0.18M	0.1%	N/A	0.229%
11/16/2020	Manatuck Hill Partners LLC	571,500	$2.42M	1.1%	+62.8%	3.050%
11/16/2020	Boothbay Fund Management LLC	46,562	$0.20M	0.0%	N/A	0.248%
11/13/2020	Stonepine Capital Management LLC	1,146,470	$4.86M	5.1%	+71.5%	6.118%
11/13/2020	Morgan Stanley	9,100	$38K	0.0%	+56.9%	0.049%

Data available starting January 2016

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Today's Range

Now: $4.19

$4.03

$4.33

50 Day Range

MA: $4.29

$4.01

$4.65

52 Week Range

Now: $4.19

$2.14

$4.95

Volume

1,079,740 shs

Average Volume

54,663 shs

Market Capitalization

$179.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Who are the company insiders with the largest holdings of DiaMedica Therapeutics?: DiaMedica Therapeutics' top insider shareholders include:
Koch Thomas Von (Major Shareholder)
David J Wambeke (Insider)
Randall Michael Giuffre (Director)
Dietrich John Pauls (CEO)
Scott Kellen (CFO)
Learn More about top insider investors at DiaMedica Therapeutics.
Who are the major institutional investors of DiaMedica Therapeutics?: DiaMedica Therapeutics' top institutional investors include:
Geode Capital Management LLC — 0.72%
Blue Trust Inc. — 0.10%
Point72 Asia Singapore Pte. Ltd. — 0.02%
Learn More about top institutional investors of DiaMedica Therapeutics stock.
Which institutional investors are buying DiaMedica Therapeutics stock?: Within the last quarter, DMAC stock was bought by institutional investors including:
Geode Capital Management LLC
Blue Trust Inc.
Point72 Asia Singapore Pte. Ltd.
Within the previous year, these company insiders have bought DiaMedica Therapeutics stock:
Koch Thomas Von (Major Shareholder)
David J Wambeke (Insider)
Randall Michael Giuffre (Director)
Dietrich John Pauls (CEO)
Scott Kellen (CFO)
Learn More investors buying DiaMedica Therapeutics stock.